Here, we demonstrated that the pharmacological inhibition of RSPO2-induced FAK/Src activation significantly impaired ovarian cancer cell growth and migration, suggesting that the RSPO2/FAK/Src axis is a druggable target. The gene discussed is RSPO2; the disease is ovarian carcinoma.